Actimab-A Extends Overall Survival, Reduces Bone Marrow Blasts in Older AML Patients

Share this content:
Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients
Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients
Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML).
READ FULL ARTICLE From News Medical
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

is free, fast, and customized just for you!




Already a member?

Sign In Now »